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ABSTRACT  
Objective: Body dysmorphic disorder (BDD) typically starts in adolescence, but evidence-based 
treatments are yet to be developed and formally evaluated in this age group. We designed an 
age-appropriate cognitive-behavioral therapy (CBT) protocol for adolescents with BDD and evaluated 
its acceptability and efficacy in a pilot randomized controlled trial.  
Method: Thirty adolescents aged 12-18 (mean=16.0,SD=1.7) with a primary diagnosis of BDD and 
their families were randomly assigned to 14 sessions of CBT delivered over four months or a control 
condition of equivalent duration, consisting of written psycho-education materials and weekly 
telephone monitoring. Blind evaluators assessed participants at baseline, mid-treatment, post-treatment, 
and at two-month follow-up. The primary outcome measure was the Yale-Brown 
Obsessive-Compulsive Scale Modified for BDD, adolescent version (mean baseline 
score=37.13,SD=4.98; range=24–43).  
Results: The CBT group showed a significantly greater improvement than the control group, both at 
post-treatment (time×group interaction coefficient [95%CI]=-11.26 [-17.22 to -5.31]; p=0.000) and at 
two-month follow-up (time×group interaction coefficient [95%CI]=-9.62 [-15.74 to -3.51]; p=0.002). 
Six (40%) participants in the CBT group and one (6.7%) in the control condition were classified as 
responders at both time points (χ2=4.658,p=.031). Improvements were also seen on secondary 
measures, including insight, depression, and quality of life at post-treatment. Both patients and their 
families deemed the treatment as highly acceptable.  
Conclusion: Developmentally tailored CBT is a promising intervention for young people with BDD, 
though there is significant room for improvement. Further clinical trials incorporating lessons learned 
in this pilot and comparing CBT and pharmacological therapies, as well as their combination, are 
warranted. 
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Clinical trial registration information—A Pilot Randomized Controlled Trial of 
Cognitive-Behaviour Therapy for Children and Adolescents With Body Dysmorphic Disorder; 
http://www.isrctn.com/ISRCTN67699666; ISRCTN67699666.  
 
Key Words: Body dysmorphic disorder; children; adolescents; cognitive-behavioral therapy; 
randomized controlled trial. 
INTRODUCTION 
Body dysmorphic disorder (BDD) is a potentially severe psychiatric disorder characterized by 
excessive preoccupation with perceived defects or flaws in physical appearance that are not observable 
or appear only slight to others. This preoccupation leads to significant distress and impairment, 
time-consuming repetitive behaviors (e.g., grooming rituals, mirror checking, reassurance seeking), 
and marked avoidance (e.g., of social situations).1 The disorder has an estimated prevalence of 
approximately 2% in community samples of adults2-4 and is associated with high levels of 
occupational and social disability, including absenteeism, unemployment, marital dysfunction, and 
reduced quality of life.5-7 
BDD has received little empirical attention in adolescents, which is surprising given that an 
adolescent onset is reported in 70% of cases, with a mean age of onset around 16 years.8 In young 
people, BDD results in major functional impairment, including social withdrawal, reduced academic 
performance, and dropping out of school.9 Furthermore, the disorder is linked with strikingly high 
suicidality rates in adolescents, with a reported 21-44% of patients attempting suicide.9-11 
Unfortunately, the disorder often goes undetected in young people, as the symptoms of BDD may be 
mistakenly interpreted as normal developmental concerns (i.e., most teenagers worry about their 
appearance to some extent). 
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There is growing evidence that cognitive-behavioral therapy (CBT) may be efficacious for 
adults with BDD.12-17 By contrast, the treatment literature for BDD in adolescents is very sparse; the 
only published evidence comes from single case studies18-20 and a small case series of six 
adolescents.21 The findings of these studies suggest that CBT is probably a feasible treatment option 
for adolescents with the disorder. Despite the lack of solid evidence, in the UK, clinical guidelines 
recommend CBT as a first-line treatment for children and adolescents with BDD.22 There is an urgent 
need to develop, evaluate, and disseminate age-appropriate treatment protocols for young people with 
BDD. 
In this study, we aimed to a) develop an age-appropriate CBT protocol for young people with 
BDD, involving their parents or carers when appropriate, and b) evaluate its acceptability and efficacy 
in a pilot randomized controlled trial (RCT). We predicted that the intervention would lead to a 
significantly greater reduction in BDD symptoms, compared to a control condition consisting of 
written psycho-education materials and weekly telephone monitoring, and that the therapeutic gains 
would be maintained two months after treatment. We also predicted that the intervention would be 
deemed acceptable and result in high levels of satisfaction in both the young people and their 
parents/carers. 
METHOD 
Design and participants 
The study was a single blind RCT with two groups conducted at a single specialist center in England, 
United Kingdom, between February 2012 and August 2014. Patients were randomly allocated (1:1 
ratio) to either 14 sessions of CBT delivered over a 4-month period or a control condition of 
equivalent duration consisting of written psycho-education materials and weekly telephone monitoring 
(henceforth “control”). Participants randomised to the control condition were offered CBT after a 
2-month follow-up. There were no changes to the trial design after its commencement or any protocol 
violations. 
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 Participants recruited to the trial were those referred to the National and Specialist OCD 
[obsessive-compulsive disorder], BDD, and Related Disorders Clinic for Young People at the 
Maudsley Hospital. In addition to the usual referral channels, the trial was widely advertised across 
child and adolescent mental health services (CAMHS) using a range of methods, including specifically 
designed leaflets/posters, talks, and distributing brief screening questionnaires within community 
CAMHS. Additionally, advertisements were placed in social media sites, relevant charities’ websites, 
and magazines for young people. A website was also created to advertise the study. Individuals 
showing interest in the treatment trial were requested to see their local CAMHS or general practitioner 
to seek a formal referral to the clinic.  
Eligibility criteria for participants were as follows: a) age ranging from 12-18 years; b) a 
DSM-IV diagnosis of BDD; c) stable psychotropic medication for 12 weeks prior to randomization (if 
relevant); d) no plans to commence or increase the dose of psychotropic medication (if relevant); e) 
willingness to receive psychological treatment; f) willingness/ability to travel to the clinic for CBT; 
and g) a score of 24 or higher on the Yale-Brown Obsessive-Compulsive Scale Modified for BDD – 
Adolescent version (BDD-YBOCS-A).23 
 Exclusion criteria were: a) current or past diagnosis of schizophrenia or bipolar affective 
disorder, current alcohol or substance dependence, severe disabling neurological disorder, global 
intellectual disability, autism spectrum disorder, or an emerging borderline personality disorder 
requiring treatment in its own right; b) suicidal intent that requires hospitalization; c) English too poor 
to engage in treatment; and d) characteristics interfering with completion of treatment (e.g., selective 
mutism). 
Interventions 
CBT: Existing adult CBT protocols/treatment manuals for BDD24, 25 were adapted to ensure 
developmentally appropriate content for young people with BDD. These adaptations were guided by 
the existing pediatric OCD26 and BDD20 literature, as well as by our own previous experience treating 
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these patients.21 For example, language was simplified, and age-appropriate worksheets and handouts 
were produced. In all cases, effort was made to include parents in psycho-education sessions at the 
start of treatment in order to ensure a shared understanding of BDD and learn how to best support the 
child in treatment. The extent to which parents/carers were included in subsequent sessions was 
decided in collaboration with the young person and guided by the individual case formulation, 
specifically considering the following factors: a) the level of parental involvement in BDD-related 
rituals, reassurance, and/or avoidance; b) the extent to which additional parental beliefs and/or 
behaviors were a barrier in treatment (e.g., high levels of parental criticism); and c) the extent to which 
parental involvement might inhibit disclosure or discussion of relevant experiences (e.g., shaming and 
humiliating experience within the family or within an intimate relationship).  
 The 14-session treatment protocol consisted of three main phases. Sessions 1-2 (90 minutes 
each) focused on psycho-education about: a) normal appearance worries versus BDD in order to 
explain why the diagnosis was made, in a way that would facilitate engagement with a psychological 
model; b) body image versus physical appearance in order to demonstrate the role that perception 
might play in BDD; c) recognizing anxiety and its reduction over time in order to provide a rationale 
for exposure and response prevention (ERP); d) developing an individualized cognitive behavioral 
formulation to offer an alternative perspective on current difficulties; and d) goal setting and 
constructing an ERP hierarchy. Sessions 3-12 (60 minutes each) focused primarily on ERP as guided 
by the hierarchy. ERP tasks were conducted in sessions with therapist assistance (e.g., going to a café 
or a swimming pool while dropping safety behaviors) as well as being set as homework tasks. Other 
optional modules (primarily mirror retraining and attention training)24, 25 were included as needed, 
determined by the individual formulation, in order to promote engagement with ERP (details in 
Supplement 1, available online). Sessions 13 and 14 (60 minutes each) included relapse prevention 
strategies and developing a plan for maintaining and building on treatment gains. 
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The treating therapists were clinical psychologists who were highly experienced in the 
delivery of CBT and with particular expertise in treating OCD and related disorders in children and 
adolescents. Additionally, the therapists received ongoing monthly supervision during the trial from 
two senior therapists with particular expertise in CBT for adults with BDD (M.A. and D.V.) and 
weekly supervision from more experienced peer therapists.  
Control group: Participants randomized to the control condition were given written materials 
containing age-appropriate information about BDD, anxiety, and the link between thoughts, emotions, 
and behaviors (for details, see Supplement 1, available online). Importantly, these materials did not 
contain information regarding the treatment of BDD. Patients were able to email or phone the clinic 
with any questions they may have about the materials and for general support. Additionally, a research 
assistant phoned each patient once a week to monitor mood and suicidal ideation/intent or other risks. 
During each call, the Patient Health Questionnaire (PHQ),27, 28 which contains a question about suicide 
intent, was completed. All participants assigned to the control condition were offered CBT after the 
end of the two-month follow-up.  
Assessment and outcomes 
All patients and their families attended an initial assessment of approximately three hours with a 
multidisciplinary specialist team. Assessment included a mental state examination and an interview 
with the young person to obtain a detailed account of their BDD symptoms, and an interview with 
parents/carers to obtain a full developmental history and an independent account of current difficulties. 
In addition, patients completed a number of standardized symptom measures. Demographic 
information (i.e., age, gender, ethnicity) was also collected.  
Diagnosis of BDD was made according to DSM-IV criteria using the BDD section of the 
Structured Clinical Interview for DSM-IV (SCID-I).29 Comorbid psychiatric diagnoses were 
established using the child version of the Anxiety Disorders Interview Schedule (ADIS-IV-C).30  
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All measures were administered at each of the time-points (baseline, post-treatment, and 
two-month follow-up). Additionally, the BDD-YBOCS-A23 and the Anxiety Appearance Inventory 
(AAI)31 were also administered at mid-treatment (session 7). 
The primary outcome measure was the BDD-YBOCS-A, a widely used 12-item 
semi-structured clinician-administered interview that rates the severity of BDD symptoms during the 
past week (score range 0-48). Treatment response was defined as at least 30% reduction in symptoms 
on the BDD-YBOCS-A.32  
Secondary outcome measures comprised self-reported measures, including the AAI,31 the 
Brown Assessment of Beliefs Scale (BABS),33, 34 the Cosmetic Procedures Screening Questionnaire 
(COPS),35 the Body Image Quality of Life Inventory (BIQLI),36, 37 and the Beck Depression Inventory 
for Youth (BDI-Y),38 as well as clinician-administered measures, including the Children's Global 
Assessment Scale (CGAS)39 and the Clinical Global Impression–Severity (CGI-S) and –Improvement 
(CGI-I) Scales.40 
Additionally, a treatment satisfaction questionnaire was developed to assess participant and 
parent/carer satisfaction with the intervention; this was administered at post-treatment to the CBT 
group only. 
Power calculation 
Based on data from two previous adult waitlist-controlled trials,12, 13 calculations showed that, in order 
to detect a large effect size (i.e., d≥0.8) on the primary outcome measure at two-sided 5% alpha and 
90% power, 11 participants would be required in each group. To allow for potential dropouts (up to 
20% expected), cell sizes were set at 15 participants in each arm. 
Randomization and concealment 
Prior to the inclusion of patients, a randomization sequence was computer-generated using permuted 
block randomization (blocks of 4 patients, 1:1 ratio), chosen to avoid imbalanced group sizes.41 
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Patients received their randomization number consecutively, based on the order of their inclusion in 
the trial. Sealed envelopes with information on treatment allocation were stored in a secure locker in 
case of emergency un-blinding. The allocation sequence was concealed from the research assessors. 
The therapist was directly informed of the treatment allocation by the trial coordinator. Blinding was 
only broken after the last patient had completed the two-month follow-up appointment.  
Implementation 
The research assessor enrolled suitable participants in the trial and gained written informed consent 
from them (if they were 16 years of age or older) and their parents/carers for their participation in the 
study. Informed assent was gained from participants younger than 16 years of age after a detailed 
description of the study had been given. Participants were either randomized to receive 14 weekly 
sessions of BDD-specific CBT over four months, followed by a two-month follow-up, or to a control 
condition of equivalent duration (i.e., four months followed by another 2 months of follow-up).  
Blinding 
Trained independent assessors who were blind to condition completed all clinician-administered 
measures at all time-points. Treating therapists and participants/parents were instructed not to discuss 
the arm that they had been allocated to with the blinded assessors, and reminder cards were placed in 
the interview rooms. Where blindness was inadvertently broken (four patients at mid-treatment, three 
at post-treatment, and one at two-month follow-up), assessors were immediately changed.  
Treatment Integrity 
A random sample of n=49 (25%) audio-recorded therapy sessions were checked for integrity, using an 
adherence-to-protocol rating form developed for this study. The rate of adherence to the treatment 
manual was 86.7%, which is considered a high rate of treatment fidelity.42  
Statistical analyses 
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Across mid-treatment, post-treatment, and follow-up, there were four missing data points on the 
BDD-YBOCS-A and a similar number of missing data points on the secondary outcome measures. 
Logistic regression analyses indicated that data were missing at random. Intent-to-treat (ITT) 
mixed-effects regression analyses for repeated measures with maximum likelihood estimation (MLE) 
of parameters were implemented in Stata. Mixed-effects models use all available data, can properly 
account for correlation between repeated measurements on the same participant, have greater 
flexibility to model time effects, and can handle missing data.43 For each outcome measure, the model 
included fixed effects of time (baseline, mid-treatment [only available for the BDD-YBOCS-A and the 
AAI], post-treatment, and two-month follow-up), study group (CBT vs control), and the interaction 
time×group. Participant effects were added as a random intercept factor to account for the variances 
between participants and within participants. Additionally, within- and between-group effect sizes for 
change across time points were calculated with Cohen’s d.44 Alpha (two-tailed) was set at p<0.05 for 
all analyses. 
Ethics and trial monitoring 
The study protocol was approved by the National Research Ethics Service Committee South East 
Coast – Kent (REC reference 11/LO/1605). External quality management of the study was provided 
by a steering committee including the project management team, carer and user representatives, expert 
advisors, and trial therapists. 
RESULTS 
Participant characteristics 
Recruitment of participants took place between February 2012 and March 2014. Table 1 shows the 
demographic and clinical characteristics of the sample, which was predominantly female and 
Caucasian. One fifth were on medication at the time of the assessment and approximately 35% had 
had previous medication and CBT. Half were completely convinced that their perceived defect was 
real (delusional insight) and nearly half expressed desire to have a cosmetic procedure at baseline. 
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Approximately 43% had current or a history of self-harm, and 17% a history of suicide attempts. More 
than half of the sample was either inconsistently or not attending school due to their BDD. Nearly 70% 
had at least one comorbid psychiatric diagnosis; the most frequent comorbidities were mood disorders 
(major depressive disorder or dysthymia; n=10, 33.3%), social phobia (n=10, 33.3%), specific phobias 
(n=8, 26.7%), and generalized anxiety disorder (n=4, 13.3%). More details can be found in Table S1 
(available online). 
- Insert Table 1 about here – 
Participants reported the following main feature(s) of concern: nose (n=7; 23.3%), hair (n=6; 
20%), skin (n=4; 13.3%), face in general (n=3; 10.0%), jaw line (n=2; 6.7%), body hair (n=2; 6.7%), 
breasts (n=2; 6.7%), stomach (n=3; 10.0%), and other (including spots, mole, bags under the eyes, 
teeth, ears, body shape, thighs, hips, weight, feet, and genitalia; n=11; 36.7%).  
Primary outcome 
The participants’ flow during the trial is depicted in Figure 1. All patients in the CBT group completed 
treatment and provided data. In the control group, one participant dropped out immediately after 
randomization, and another was lost to follow-up. 
- Insert Figure 1 about here - 
Table 2 shows the estimated means and standard errors (SE) from the mixed-effects model 
for each group and time-point. Raw means and SDs per group across measurement points for the 
BDD-YBOCS-A appear in Table S2, available online. In the linear mixed-effects regression model, 
the time×group interaction was not significant at mid-treatment (coefficient [95%CI]=-4.19 [-10.15 to 
1.76]; p=.167) but, as expected, it was significant both at post-treatment (coefficient [95%CI]=-11.26 
[-17.22 to -5.31]; p=0.000) and at two-month follow-up (coefficient [95%CI]=-9.62 [-15.74 to -3.51]; 
p=0.002), favoring the CBT group. Post-hoc between-group contrasts showed significantly lower 
BDD-YBOCS-A scores in the CBT group at post-treatment (estimated mean difference between CBT 
and control groups at post-treatment=-10.20 [95%CI=-16.02 to -4.38], SE=2.97; p=0.001). These 
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gains were maintained at the two-month follow-up (estimated mean difference=-8.56 [95%CI=-14.54 
to -2.58], SE=3.05; p=0.005).  
- Insert Table 2 and Figure 2 about here – 
Using one definition of treatment response (≥ 30% reduction in the BDD-YBOCS),32 6 
(40%) participants in the CBT group and one (6.7%) participant in the control condition were 
classified as responders at both post-treatment and follow-up (χ2=4.658, p=.031).  
Between-groups effect sizes (for completers) were 1.13 (95%CI=0.31 to 1.96) at 
post-treatment and 0.85 (95%CI=0.02 to 1.69) at follow-up (Table S2, available online). 
Within-group effect sizes at post-treatment were 1.47 (0.46 to 2.47) and 0.32 (-0.29 to 0.94) for the 
CBT and control groups, respectively. Similarly, at two-month follow-up, within-group effect sizes 
were 1.38 (0.34 to 2.41) and 0.35 (-0.45 to 1.14), respectively (Table S2, available online). 
Secondary outcomes 
Table 2 shows the estimated means, standard error, and results of the mixed-effects model for all the 
secondary outcomes. Raw means and SD per group across measurement points for these variables are 
shown in Table S2 (available online). Overall, results from the mixed-effects models in the secondary 
measures were consistent with the magnitude of the between- and within-group effect sizes both at 
post-treatment and at two-month follow-up (see Table S2, available online). 
The time×group interactions were significant for all the self-reported measures (all 
p’s≤0.007) at post-treatment, favoring the CBT condition; this trend was maintained at two-month 
follow-up, although some of the interaction effects failed to reach statistical significance (see Table 
2). 
Eight (53%) CBT-treated patients were classed as improved or much improved on the 
clinician-rated CGI-I, compared to 0 in the control condition at post-treatment (see Figure S1, 
available online). 
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Treatment satisfaction and acceptability 
Thirteen parents and 12 young people from the group receiving CBT provided data on treatment 
satisfaction and acceptability. Eleven (91.7%) adolescents reported high levels of satisfaction with the 
treatment received, stating that they were very happy or happy with their treatment. Similarly, a 
majority of parents/carers (76.9%) judged the treatment to be very convenient or convenient. Eleven 
(91.7%) patients and 11 (91.7%) parents reported that CBT had taught them (or their children) many 
or some useful techniques to cope with BDD. Finally, 11 (91.7%) patients and 11 (84.6%) parents 
stated that the treatment had helped them (or their children) to greatly improve or somewhat improve 
the child’s BDD problems. 
Protocol deviations  
The protocol stipulated duration of 14 CBT sessions over four months, but eight out of the 15 patients 
in the CBT group required more time to complete treatment (mean and median=18 weeks; range=13–
28).  
Three participants obtained or changed treatment off-protocol during their involvement in the 
trial. One participant (control group) discontinued medication (fluoxetine 10mg) without medical 
consultation approximately one month after being randomized. One patient (CBT group) started 
decreasing medication (fluoxetine 20mg) until discontinuation after the end of the CBT sessions and 
before they had reached the two-month follow-up. A third patient (CBT group) commenced fluoxetine 
(up to 40mg) during the active treatment phase (between sessions 1 and 7) and started additional 
psychological treatment in an inpatient psychiatric unit at post-treatment due to the persistence of 
severe BDD concerns and a suicide attempt (participant’s BDD-YBOCS-A score at baseline=41; score 
at post-treatment=46). 
Adverse events 
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Two participants –one in each condition– attempted suicide during the trial. The attempts consisted of 
drug overdoses that required emergency attendance at hospital. Both patients stayed in the trial after 
the overdoses, though one patient in the CBT group (mentioned in the previous section) deviated from 
protocol and received additional pharmacological and psychological treatment in an inpatient unit. The 
participant in the control condition continued to be monitored by their local child and adolescent 
mental health service (this monitoring was not focused on the BDD symptoms and did not include 
active treatment for BDD).  
DISCUSSION 
To our knowledge, this is the first RCT to test the feasibility, acceptability, and efficacy of a 
developmentally tailored CBT protocol for young people with BDD. Both the patients and their 
families deemed the intervention highly acceptable and useful. CBT was superior to a control 
condition of equivalent duration (consisting of psycho-education materials and weekly risk 
monitoring) on both primary and secondary measures (e.g., insight, depression, general function) and 
the gains were generally maintained at two-month follow-up. Between-group effect sizes were large 
(1.13 at post-treatment and 0.85 at follow-up), as were the within-group effect sizes of CBT (1.47 at 
post-treatment and 1.38 at follow-up).  
 The results are broadly comparable to those in the adult CBT trials for BDD,15-17 which 
reported response rates ranging from 48% to 61% and within-group effect sizes ranging from 0.83 to 
1.30 after 12 weeks of treatment. Although these comparisons need to be made cautiously, because 
recruited samples and treatment protocols differ, our results suggest that CBT can also be 
developmentally tailored and successfully delivered to young people with the disorder, supporting the 
UK National Institute for Health and Care Excellence guidelines.22 Despite this, the results could be 
described as modest, as only 40% of the treated patients were considered responders according to one 
prevailing operational definition of treatment response in BDD32. Employing another definition, 
approximately 53% of CBT-treated patients were classed as improved or much improved on the 
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clinician-rated CGI-I. The mean BDD-YBOCS score at post-treatment and follow-up (around 25 
points) corresponds to mild/moderate BDD symptoms, suggesting that there is considerable room for 
improvement. 
It is important to note that ours was a severely ill sample (11 patients [37% of the sample] 
had BDD-YBOCS scores over 40, and a further 6 patients had scores of 38 or 39, indicating very 
severe symptoms). Half of the sample was classed as having no insight (delusional) at baseline. A 
substantial proportion had a history of self-harm and suicidal attempts. Nearly 60% were off school or 
only attending sporadically due to their BDD symptoms. Nearly half desired cosmetic procedures. 
Though the study protocol stipulated that the 14 CBT sessions should be delivered in four months, 
many patients missed sessions or had unproductive sessions, which were used to deal with low mood, 
family conflict, or risky situations like suicidal ideation or attempts. This resulted in a protocol 
adherence of around 87%, which is somewhat lower than that reported in the OCD literature.45 Outside 
the tight control conditions of a clinical trial, we suspect that many of these patients would have 
dropped out from treatment. Our experience from this trial suggests that a considerable proportion of 
youths with BDD may require longer than 14 sessions, delivered weekly but with flexibility in terms 
of location and time of appointments, in order to achieve symptom relief. In support of this possibility, 
two recent adult trials12,14 showed that further improvements occurred when treatment was prolonged 
beyond the acute phase (12 sessions). 
Compared to the adult BDD trials, our trial had a lower proportion of male patients (only 
13%). A similar female predominance was observed in previous pediatric BDD studies.9, 10 It is 
unclear whether BDD is less prevalent in adolescent boys or simply harder to detect. Further 
epidemiological research will be required to address this question and possibly identify barriers to 
seeking help amongst adolescent males. BDD is associated with considerable stigma and reluctance to 
disclose symptoms46, 47 and perhaps this is particularly problematic in adolescent boys.  
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This study had some limitations. First, there were a number of protocol deviations. These 
included a slightly longer duration and higher variability of the active treatment phase for the CBT 
group compared to the control group (a median of 18 weeks [range 13-28 weeks] instead of the 
predicted 17.4 weeks [4 months] needed to complete treatment). Additionally, three participants (two 
in the CBT group and one in the control group) either discontinued (n=2) or commenced (n=1) 
medication during the trial. Exclusion of all data points after these medication changes did not alter the 
results. Second, blindness to condition was inadvertently broken in eight occasions during the duration 
of the trial. However, assessors were immediately changed when that occurred, thus minimizing the 
consequences of the un-blinding in posterior assessments. Third, though adequately powered to test 
the study hypotheses, this pilot study was too small to examine whether comorbidity (e.g., depression), 
low insight, or other variables are predictive of treatment outcome in youths with BDD. The 
identification of reliable predictors of outcome will be invaluable to inform future refinements of the 
protocol and to devise more personalized interventions. Fourth, the study was conducted in the context 
of a highly specialist clinic and the results may not generalize to other settings or less complex BDD 
populations. Finally, we used a control condition which included psychoeducation materials and 
careful monitoring of risk; however, despite weekly phone calls, patients in the control condition did 
not receive a comparable amount of therapist contact, potentially resulting in an inherent advantage for 
the CBT group beyond the active elements of the intervention (that is, non-specific effects associated 
with therapist contact). A larger RCT comparing an optimized version of this treatment with an active 
control condition, such as anxiety management,13 is warranted. Similarly, a longer follow-up of these 
patients is also warranted to establish the durability of the treatment. 
To conclude, developmentally tailored CBT is a promising intervention for young people with 
BDD, though there is substantial room for improvement and further need to compare it with active 
control conditions. Further clinical trials comparing optimized CBT and pharmacological therapies, as 
well as their combination, both in young people and adults with BDD, are sorely needed. 
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FIGURES 
 
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram. Note: CBT = 
cognitive-behavioral therapy; ITT = intent-to-treat. 
 
Figure 2. Time×group interaction effects on the primary outcome measure (Yale-Brown 
Obsessive-Compulsive Scale Modified for BDD–Adolescent version, BDD-YBOCS-A), derived from 
the mixed-effects regression model. Note: Error bars indicate 95% CI. CBT = cognitive-behavioral 
therapy; 2m FU = 2-month follow-up. 
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Table 1. Demographic and Clinical Characteristics of the Sample. 
 
Combined 
sample 
(N=30) 
 
CBT group 
(n=15) 
 
Control group 
(n=15) 
 Mean SD  Mean SD  Mean SD 
Age at assessment 16.0 1.7  16.1 1.8  15.8 1.5 
Age of BDD onset 12.5 1.9  12.2 2.4  12.8 1.4 
 n %  n %  n % 
Gender         
  Female 26 86.7  11 73.3  15 100 
  Male 4 13.3  4 26.7  0 0 
Ethnicity         
  White 24 80.0  14 93.3  10 66.7 
  Black 2 6.7  0 0  2 13.3 
  Mixed 3 10.0  1 6.7  2 13.3 
  Asian 1 3.3  0 0  1 6.7 
Presence of comorbidities (any)a         
  Yes 20 66.7  11 73.3  9 60.0 
  No 10 33.3  4 26.7  6 40.0 
Medicated at time of assessment         
  Yes 6b  20.0  3 20.0  3 20.0 
  No 24 80.0  12 80.0  12 80.0 
Previous SSRI         
  Yes 11 36.7  7 46.7  4 26.7 
  No 19 63.3  8 53.3  11 73.3 
Previous CBT for BDD         
  Yes 11 36.7  7 46.7  4 26.7 
  No 19 63.3  8 53.3  11 73.3 
Delusional BDD at baseline         
  Yes 15 51.7  8 57.1  7 46.7 
  No 14 48.3  6 42.9  8 53.3 
Desire for cosmetic procedure at baseline         
  Yes 14 46.7  5 33.3  9 53.3 
  No 16d 53.3  10c 67.7  6 46.7 
History of or current self-harm         
  Yes 13 43.3  6 40.0  7 46.7 
  No 17 56.7  9 60.0  8 53.3 
History of suicide attempts         
  Yes 5 16.7  4 26.7  1 6.7 
  No 25 83.3  11 73.3  14 93.3 
Attending school at baseline         
  Yes 13 43.3  6 40.0  7 46.6 
  Part-time (due to BDD)e 6 20  2 13.3  4 26.7 
  No (dropped-out due to BDD) 11 36.7  7 46.7  4 26.7 
Note: BDD = body dysmorphic disorder; CBT = cognitive-behavioral therapy; SSRI = selective serotonin reuptake inhibitors. 
a According to the Anxiety Disorders Interview Schedule–child version. b Five patients were on SSRIs and one on quetiapine. c Patients are 
classified as having delusional BDD beliefs if their total score in the Brown Assessment of Beliefs Scale (BABS) is 18 or more, and if 
they score 4 on the first item, indicating they are completely convinced that their belief is accurate. d This group includes one young person 
who did not have further desire for a cosmetic procedure after having had laser surgery for acne. e Includes missing days, missing lessons, or 
being late due to BDD behaviors.
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Table 2. Model Estimates for Each Treatment Group Across Time-Points and Results of the Group×Time Interaction Effects From the Linear Mixed-Effects Models  
 
Measures 
Model estimates  Group × Time interaction effects  
Baseline 
Mid-treatment 
(session 7) 
Post-treatment 
(session 14) 
Two-month 
follow-up 
 Mid-treatment (session 7)  
outcomes 
Post-treatment (session 14)  
outcomes 
Two-month follow-up  
outcomes 
Mean SE Mean SE Mean SE Mean SE 
 Coefficient 
(95%CI) p value 
Coefficient 
(95%CI) p value 
Coefficient 
(95%CI) p value 
BDD-YBOCS-A          -4.19 (-10.15 to 1.76) 0.167 -11.26 (-17.22 to -5.31) 0.000 -9.62 (-15.74 to -3.51) 0.002 
CBT 37.67 2.07 30.53 2.07 24.53 2.07 24.67 2.07        
Control 36.60 2.07 33.66 2.13 34.73 2.13 33.22 2.24        
AAI          -5.08 (-13.63 to 3.46) 0.243 -14.75 (-23.28 to -6.23) 0.000 -7.59 (-16.45 to 1.27) 0.093 
CBT 39.93 3.02 30.07 3.02 19.39 3.09 21.57 3.17        
Control 42.80 3.02 38.02 3.18 37.01 3.10 32.02 3.26        
BABS          – – -5.46 (-9.15 to -1.77) 0.004 -0.94 (-4.59 to 2.71) 0.615 
CBT 19.01 1.34 – – 14.32 1.34 15.87 1.32        
Control 19.33 1.32 – – 20.10 1.42 17.50 1.42        
COPS          – – -15.42 (-26.73 to -4.12) 0.007 -11.57 (-23.21 to 0.72) 0.051 
CBT 58.07 3.68 – – 36.15 3.89 39.72 4.01        
Control 60.87 3.68 – – 54.37 4.02 54.09 4.15        
BIQLI          – – 21.54 (6.90 to 36.19) 0.004 5.44 (-9.83 to 20.71) 0.485 
CBT -35.43 4.06 – – -11.83 4.21 -21.52 4.74        
Control -30.39 4.37 – – -28.33 4.55 -21.91 4.55        
BDI-Y          – – -15.75 (-25.61 to -5.90) 0.002 -5.15 (-15.27 to 4.97) 0.319 
CBT 69.07 3.40 – – 53.78 3.59 60.84 3.59        
Control 66.20 3.40 – – 66.71 3.49 63.13 3.69        
CGAS          – – 7.89 (1.40 to 14.38) 0.017 9.75 (3.15 to 16.35) 0.004 
CBT 40.20 2.56 – – 50.47 2.61 51.13 2.56        
Control 41.20 2.56 – – 43.57 2.62 42.39 2.74        
CGI-S          – – -1.40 (-2.17 to -0.64) 0.000 -0.74 (-1.53 to 0.05) 0.066 
CBT 5.06 0.28 – – 3.40 0.27 3.53 0.27        
Control 4.93 0.27 – – 4.69 0.28 4.14 0.29        
Note: AAI = Appearance Anxiety Inventory; BABS = Brown Assessment of Beliefs Scale; BDD-YBOCS-A = Yale-Brown Obsessive-Compulsive Scale Modified for Body 
Dysmorphic Disorder–Adolescent version; BDI-Y = Beck Depression Inventory-Youth; BIQLI = Body Image Quality of Life Inventory; CBT = cognitive-behavioral 
therapy; CGAS = Children's Global Assessment Scale; CGI-S = Clinical Global Impression–Severity; COPS = Cosmetic Procedures Screening Questionnaire.
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SUPPLEMENT 1 
Cognitive-Behavioral Therapy (CBT) Group: Additional Modules 
The following modules were also included in the treatment manual and were used as appropriate 
depending on the case formulation, although they were not the main focus of treatment: a) mirror 
retraining; b) attention training; c) imagery rescripting for past aversive experiences (e.g., bullying, 
teasing); d) relaxation training; e) behavioral activation; f) mindfulness; g) distancing thoughts 
technique; and g) the “inner bully” technique. The emphasis of the treatment was exposure with 
response prevention (ERP) tasks. These additional modules were thus not the main focus of treatment, 
but rather used as appropriate, to either enhance ERP tasks or to enable the young person to fully 
engage in EPR tasks. This depended on the case formulation; for example, mirror retraining was used 
if the young person was particularly involved in rituals involving mirrors, and attention training was 
completed if young people were unable to effectively manipulate their internal focus of attention when 
doing exposure tasks. Among the group of 15 patients receiving CBT, 66.7% (n=10) completed the 
mirror retraining module, 53.3% (n=8) completed the attentional training module, 20.0% (n=3) the 
inner bully module, 6.7% (n=1) the imagery rescripting technique, and another 6.7% (n=1) completed 
the distancing thoughts module.  
 
Control group: Written Psycho-Education Materials 
Participants in the control group were given the following reading materials:  
• Week 1 
- Claiborn J, Pedrick C. The BDD Workbook: Overcome Body Dysmorphic Disorder and End 
Body Image Obsessions. Oakland, CA: New Harbinger Publications, Inc; 2002: 17-20. 
- Phillips KA. The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. 
New York, NY: Oxford University Press; 2005: 3-24.  
• Week 7 
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- Claiborn J, Pedrick C. The BDD Workbook: Overcome Body Dysmorphic Disorder and End 
Body Image Obsessions. Oakland, CA: New Harbinger Publications, Inc.; 2002: 26-27, 36-39. 
• Week 14 
- Veale D, Willson R, Clarke A. Overcoming Body Image Problems including Body 
Dysmorphic Disorder: A self-help guide using Cognitive Behavioral Therapy. London, UK: 
Constable & Robinson Ltd.; 2009: 1-14. 
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A.  
 
B.  
 
Figure S1. Results of the Clinical Global Impression (CGI) – Improvement in each treatment group at 
post-treatment (A) and at two-month follow-up (B). Note that at the two-month follow-up clinicians 
rated improvement relative to post-treatment. CBT = cognitive-behavioral therapy. 
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Table S1. Detailed Comorbidities at Baseline, According to the Anxiety Disorders Interview Schedule 
– Child Version 
 
Combined 
sample 
(N=30) 
 
CBT group 
(n=15) 
 
Control group 
(n=15) 
 n %  n %  n % 
Separation Anxiety Disorder 0 0  0 0  0 0 
Social Phobia 10 33.3  5 33.3  5 33.3 
Specific Phobia 8 26.7  4 26.7  4 26.7 
Panic Disorder 0 0  0 0  0 0 
Agoraphobia With Panic Disorder 0 0  0 0  0 0 
Agoraphobia Without Panic Disorder 0 0  0 0  0 0 
Generalized Anxiety Disorder 4 13.3  3 20  1 6.7 
Obsessive-Compulsive Disorder 1 3.3  0 0  1 6.7 
Posttraumatic (or Acute) Stress Disorder 0 0  0 0  0 0 
Dysthymia 3 10.0  2 13.3  1 6.7 
Major Depressive Disorder 7 23.3  3 20.0  4 26.7 
Attention-Deficit/Hyperactivity Disorder 1 3.3  0 0  1 6.7 
Substance Abuse 0 0  0 0  0 0 
Schizophrenia 0 0  0 0  0 0 
Selective Mutism 0 0  0 0  0 0 
Eating Disorders 1 3.3  1 6.7  0 0 
Somatoform Disorders 0 0  0 0  0 0 
Note: CBT = cognitive-behavioral therapy. 
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Table S2. Raw Means and Standard Deviations by Treatment Group Across Time-Points and Cohen’s d Effect Sizes at Each Time-Point  
Note: AAI = Appearance Anxiety Inventory; BABS = Brown Assessment of Beliefs Scale; BDD-YBOCS-A = Yale-Brown Obsessive-Compulsive Scale Modified for Body 
Dysmorphic Disorder – Adolescent version; BDI-Y = Beck Depression Inventory-Youth; BIQLI = Body Image Quality of Life Inventory; CBT = cognitive-behavioral 
therapy; CGAS = Children's Global Assessment Scale; CGI-S = Clinical Global Impression – Severity; COPS = Cosmetic Procedures Screening Questionnaire. 
Measures 
Baseline 
Mid-treatment  
(session 7) 
Post-treatment 
(session 14) 
Two-month  
follow-up 
 Cohen’s d effect sizes 
 Mid-treatment (session 7) Post-treatment (session 14) Two-month follow-up 
n Mean SD n Mean SD n Mean SD n Mean SD 
 Within-group 
(95% CI) 
Between-group 
(95% CI) 
Within-group 
(95% CI) 
Between-group 
(95% CI) 
Within-group 
(95% CI) 
Between-group 
(95% CI) 
BDD-YBOCS-A               0.42 (-0.35 to 1.20)  1.13 (0.31 to 1.96)  0.85 (0.02 to 1.69) 
CBT 15 37.67 4.53 15 37.67 4.53 15 24.53 11.31 15 24.67 12.32  0.95 (0.24 to 1.67)  1.47 (0.46 to 2.47)  1.38 (0.34 to 2.41)  
Control 15 36.60 5.50 15 36.60 5.50 14 34.79 5.67 12 34.79 8.87  0.51 (-0.06 to 0.96)   0.32 (-0.29 to 0.94)   0.35 (-0.45 to 1.14)  
AAI               0.58 (-0.21 to 1.38)  1.60 (0.71 to 2.50)  0.84 (-0.03 to 1.70) 
CBT 15 39.93 14.22 15 30.53 8.81 14 18.57 13.07 13 20.54 14.14  0.67 (-0.01 to 1.35)  1.56 (0.39 to 2.74)  1.37 (0.30 to 2.43)  
Control 15 42.80 7.39 14 33.71 5.77 14 36.86 9.42 12 31.67 12.34  0.64 (0.15 to 1.13)  0.70 (-0.01 to 1.40)  1.07 (0.10 to 2.05)  
BABS               –  1.26 (0.43 to 2.09)  0.26 (-0.54 to 1.06) 
CBT 14 19.21 4.74 – – – 14 13.60 6.80 15 15.87 6.85  –  0.92 (0.27 to 1.57)  0.55 (-0.08 to 1.19)  
Control 15 19.33 3.73 – – – 14 20.43 3.34 12 17.50 5.49  –  -0.31 (-0.88 to 0.27)  0.39 (-0.40 to 1.17)  
COPS    – – –         –  1.20 (0.30 to 2.10)  0.97 (0.05 to 1.88) 
CBT 15 58.07 15.27 – – – 13 35.15 17.56 12 38.92 17.57  –  1.39 (0.21 to 2.58)  1.16 (0.10 to 2.23)  
Control 15 60.87 10.21 – – – 12 54.67 14.72 11 54.36 14.03  –  0.46 (-0.10 to 1.02)  0.50 (-0.02 to 1.01)  
BIQLI    – – –         –  -0.92 (-1.82 to -0.03)  -0.09 (-1.00 to 0.83) 
CBT 14 -35.21 11.12 – – – 13 -11.31 23.25 10 -20.30 12.90  –  -1.36 (-2.78 to 0.07)  -1.24 (-2.65 to 0.17)  
Control 12 -31.17 13.29 – – – 11 -28.73 11.59 11 -21.73 18.92  –  -0.20 (-0.93 to 0.54)  -0.56 (-1.29 to 0.17)  
BDI-Y    – – –         –  0.94 (0.10 to 1.78)  0.24 (-0.59 to 1.07) 
CBT 15 69.07 13.27 – – – 13 52.23 18.35 13 60.15 14.57  –  1.05 (-0.02 to 2.13)  0.64 (-0.05 to 1.33)  
Control 15 66.20 10.78 – – – 14 66.71 12.07 12 63.42 12.03  –  -0.04 (-0.56 to 0.47)  -0.24 (-0.02 to 0.49)  
CGAS    – – –         –  -0.53 (-.32 to 0.26)  -0.81 (-1.63 to 0.02) 
CBT 15 40.20 7.81 – – – 14 49.86 12.56 15 51.13 13.98  –  -0.86 (-1.46 to -0.26)  -0.90 (-1.56 to -0.24)  
Control 15 41.20 7.53 – – – 14 43.93 9.65 12 41.75 7.72  –  -0.30 (-0.76 to 0.15)  -0.07 (-0.70 to 0.56)  
CGI-S    – – –         –  1.16 (0.34 to 1.99)  1.16 (0.34 to 1.99) 
CBT 15 5.07 0.80 – – – 15 3.40 1.30 15 3.53 1.55  –  1.51 (0.56 to 2.46)  1.51 (0.56 to 2.46)  
Control 15 4.93 0.80 – – – 14 4.64 0.74 12 4.17 0.94  –  0.38 (-0.26 to 1.01)  0.38 (-0.26 to 1.01)  
